

***IN VIVO* METABOLISM IN PRECLINICAL DRUG DEVELOPMENT**

SEVIM ROLLAS

Marmara University, Istanbul, Turkey

Contents

- 1 Introduction
- 2 *In Vivo* Metabolism of Drug Candidates
 - 2.1 Isolation and Identification of Metabolites
 - 2.2 Synthesis of Metabolites
 - 2.3 Protein Binding of Metabolites
 - 2.4 Preclinical Experimental Studies
- 3 *In Vivo* Metabolism of Prodrugs
 - 3.1 Ester and Amide Prodrugs
 - 3.2 Other Prodrugs
 - 3.3 Metabolic Stability of Prodrugs
- 4 Acyl Glucuronides
- 5 Role of Active Metabolites in Preclinical Drug Development
- 6 Current Approaches for Evaluating Preclinical *In Vivo* Metabolism
- 7 Conclusion
- References

1 INTRODUCTION

Drug biotransformation plays an important role in the absorption, distribution, metabolism, excretion, and toxicology (ADMET) properties. Undesirable ADMET properties are the cause of many drug development failures [1–3]. Many toxic side effects (carcinogenicity, tissue necrosis, apoptosis, hypersensitivity, teratogenicity) of